Cingulate Inc. (CINGW)
0.05
-0.03 (-37.50%)
At close: Jan 15, 2025, 3:20 PM
0.05
0.00%
After-hours Jan 15, 2025, 03:20 PM EST
undefined% (undefined)
| Bid | 0.04 |
| Market Cap | 9.06M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.732 |
| PE Ratio (ttm) | -0.03 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 0.08 |
| Volume | 38,132 |
| Avg. Volume (20D) | 0 |
| Open | 0.07 |
| Previous Close | 0.08 |
| Day's Range | 0.04 - 0.08 |
| 52-Week Range | 0.04 - 0.08 |
| Beta | undefined |
About CINGW
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company's lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was fo...
Industry Biotechnology
Sector Healthcare
IPO Date n/a
Employees 13
Stock Exchange NASDAQ
Ticker Symbol CINGW
Website https://www.cingulate.com